Carregant...
Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
The treatment of chronic hepatitis C has been revolutionized with the introduction of direct-acting antivirals (DAAs). However, some patients are not cured with first-line treatment. Sofosbuvir/velpatasvir/voxilaprevir is a fixed-dose combination of a polymerase inhibitor, an NS5A inhibitor, and a p...
Guardat en:
| Publicat a: | Infect Drug Resist |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6662169/ https://ncbi.nlm.nih.gov/pubmed/31413603 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S171338 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|